These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25663577)

  • 1. Minimal clinically important differences in the EORTC QLQ-BN20 in patients with brain metastases.
    Wong E; Zhang L; Kerba M; Arnalot PF; Danielson B; Tsao M; Bedard G; Thavarajah N; Cheon P; Danjoux C; Pulenzas N; Chow E
    Support Care Cancer; 2015 Sep; 23(9):2731-7. PubMed ID: 25663577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL.
    Caissie A; Nguyen J; Chen E; Zhang L; Sahgal A; Clemons M; Kerba M; Arnalot PF; Danjoux C; Tsao M; Barnes E; Holden L; Danielson B; Chow E
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1238-45. PubMed ID: 22172909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
    Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy.
    Raman S; Ding K; Chow E; Meyer RM; Nabid A; Chabot P; Coulombe G; Ahmed S; Kuk J; Dar AR; Mahmud A; Fairchild A; Wilson CF; Wu JSY; Dennis K; DeAngelis C; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2016 Oct; 25(10):2535-2541. PubMed ID: 27138964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal important differences in the EORTC QLQ-C15-PAL to determine meaningful change in palliative advanced cancer patients.
    Bedard G; Zeng L; Zhang L; Lauzon N; Holden L; Tsao M; Danjoux C; Barnes E; Sahgal A; Poon M; Hicks K; Chow E
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e38-46. PubMed ID: 23551493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases.
    Zeng L; Chow E; Zhang L; Tseng LM; Hou MF; Fairchild A; Vassiliou V; Jesus-Garcia R; Alm El-Din MA; Kumar A; Forges F; Chie WC; Bedard G; Bottomley A
    Support Care Cancer; 2012 Dec; 20(12):3307-13. PubMed ID: 22562607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.
    Maringwa J; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Reeve BB; Gotay C; Greimel E; Flechtner H; Cleeland CS; Schmucker-Von Koch J; Weis J; Van Den Bent MJ; Stupp R; Taphoorn MJ; Bottomley A;
    Ann Oncol; 2011 Sep; 22(9):2107-2112. PubMed ID: 21324954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer.
    Bedard G; Zeng L; Zhang L; Lauzon N; Holden L; Tsao M; Danjoux C; Barnes E; Sahgal A; Poon M; Chow E
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):109-17. PubMed ID: 23551530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EORTC QLQ-BN20 for assessment of quality of life in patients receiving treatment or prophylaxis for brain metastases: a literature review.
    Leung A; Lien K; Zeng L; Nguyen J; Caissie A; Culleton S; Holden L; Chow E
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):693-700. PubMed ID: 22098285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for overall quality of life in patients with advanced cancer.
    Cramarossa G; Chow E; Zhang L; Bedard G; Zeng L; Sahgal A; Vassiliou V; Satoh T; Foro P; Ma BB; Chie WC; Chen E; Lam H; Bottomley A
    Support Care Cancer; 2013 Jun; 21(6):1709-16. PubMed ID: 23338229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of health-related quality of life in Lithuanian brain tumor patients using the EORTC brain cancer module.
    Bunevičius A; Tamašauskas Š; Tamašauskas A; Deltuva V
    Medicina (Kaunas); 2012; 48(11):588-94. PubMed ID: 23455894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC QLQ-C15-PAL quality of life scores in patients with advanced cancer referred for palliative radiotherapy.
    Caissie A; Culleton S; Nguyen J; Zhang L; Zeng L; Holden L; Dennis K; Chan E; Jon F; Tsao M; Danjoux C; Sahgal A; Barnes E; Koo K; Chow E
    Support Care Cancer; 2012 Apr; 20(4):841-8. PubMed ID: 21538099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in patients with primary and metastatic brain cancer as reported in the literature using the EORTC QLQ-BN20 and QLQ-C30.
    Chiu L; Chiu N; Zeng L; Zhang L; Popovic M; Chow R; Lam H; Poon M; Chow E
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):831-7. PubMed ID: 23252363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translation and validation of the Urdu version of the European organization for research and treatment of cancer core quality of life questionnaire (EORTC QLQ-C30) and brain module (QLQ-BN20) in primary brain tumor patients.
    Zahid N; Martins RS; Zahid W; Khalid W; Azam I; Bhamani SS; Asad N; Ahmad K; Jabbar AA; Shamim MS; Khan RJ; Javed G; Bari E; Enam SA
    J Patient Rep Outcomes; 2021 Sep; 5(1):79. PubMed ID: 34487251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients.
    Taphoorn MJ; Claassens L; Aaronson NK; Coens C; Mauer M; Osoba D; Stupp R; Mirimanoff RO; van den Bent MJ; Bottomley A;
    Eur J Cancer; 2010 Apr; 46(6):1033-40. PubMed ID: 20181476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors of overall well-being using the EORTC QLQ-C15-PAL extracted from the EORTC QLQ-C30.
    Lam K; Zeng L; Zhang L; Tseng LM; Hou MF; Fairchild A; Vassiliou V; Jesus-Garcia R; Alm El-Din MA; Kumar A; Forges F; Chie WC; Sahgal A; Poon M; Chow E
    J Palliat Med; 2013 Apr; 16(4):402-8. PubMed ID: 23458649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatigue scores in patients with brain metastases receiving whole brain radiotherapy.
    Pulenzas N; Khan L; Tsao M; Zhang L; Lechner B; Thavarajah N; Barnes E; Danjoux C; Holden L; Lauzon N; Sheehan P; Bedard G; Chow E
    Support Care Cancer; 2014 Jul; 22(7):1757-63. PubMed ID: 24510194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in patients with limited (1-3) brain metastases undergoing stereotactic or whole brain radiotherapy : A prospective study of the DEGRO QoL working group.
    Steinmann D; Vordermark D; Gerstenberg W; Aschoff R; Gharbi N; Müller A; Schäfer C; Theodorou M; Wypior HJ; Geinitz H;
    Strahlenther Onkol; 2020 Jan; 196(1):48-57. PubMed ID: 31418046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the Chinese version of EORTC QLQ-BN20 for patients with brain cancer.
    Zhang K; Tian J; He Z; Sun W; Pekbay B; Lin Y; Wu D; Zhang J; Chen P; Guo H; Wan Y; Wang M; Yang S; Zheng J; Zhang L
    Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12832. PubMed ID: 29461664
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.